AEM vs ARIS

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

ARIS exhibits a stable financial health profile with a Piotroski F-Score of 4/9 and a strong balance sheet characterized by low debt/equity (0.36). While the company is delivering explosive triple-digit growth in revenue (104.2%) and earnings (121.7%), the stock is significantly overvalued, trading at $18.76 against a Graham Number of $8.06 and an Intrinsic Value of $12.09. The combination of a bearish technical trend (0/100) and a high P/E ratio suggests that the market has already priced in much of the future growth, creating a high-risk entry point despite strong fundamentals.